In a potentially game-changing decision, the Department of Health and Human Services (HHS) recently recommended the DEA to consider reclassifying cannabis from its Schedule I status — a classification that denotes no medical value, on par with substances like heroin — to Schedule III.

Related Content: Cannabis Stocks Soar As Gov Health Officials Call On DEA To Reschedule Marijuana: Is Legalization In Sight?

This historic recommendation sent ripples through the market, as depicted in a recent report by Viridian Capital Advisors.

Insights From Viridian Report

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.